 Connection
Srikanth Vallurupalli to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Srikanth Vallurupalli has written about Diabetes Mellitus, Type 2.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.423 |
|
|
|
-
Salah HM, Al'Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, Mounsey JP, Greene SJ, McGuire DK, Lopes RD, Fudim M. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022 02 05; 21(1):20.
Score: 0.129
-
Salah HM, Al'Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, Mounsey JP, Greene SJ, McGuire DK, Lopes RD, Fudim M. Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. Am Heart J. 2021 03; 233:86-91.
Score: 0.120
-
Salah HM, Al'Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, Mounsey JP, Greene SJ, McGuire DK, Lopes RD, Fudim M. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials. Am Heart J. 2021 02; 232:10-22.
Score: 0.118
-
Vallurupalli S. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure. Ann Pharmacother. 2010 Feb; 44(2):387-90.
Score: 0.056
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|